- Home
- PBYI vs AVTX Comparison
PBYI vs AVTX Comparison
Compare PBYI & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- AVTX
- Stock Information
- Founded
- PBYI 2010
- AVTX 2011
- Country
- PBYI United States
- AVTX United States
- Employees
- PBYI N/A
- AVTX N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- AVTX Health Care
- Exchange
- PBYI Nasdaq
- AVTX Nasdaq
- Market Cap
- PBYI 171.7M
- AVTX 138.8M
- IPO Year
- PBYI N/A
- AVTX 2015
- Fundamental
- Price
- PBYI $4.56
- AVTX $11.41
- Analyst Decision
- PBYI Strong Buy
- AVTX Strong Buy
- Analyst Count
- PBYI 1
- AVTX 8
- Target Price
- PBYI $7.00
- AVTX $31.00
- AVG Volume (30 Days)
- PBYI 980.5K
- AVTX 214.6K
- Earning Date
- PBYI 11-06-2025
- AVTX 11-06-2025
- Dividend Yield
- PBYI N/A
- AVTX N/A
- EPS Growth
- PBYI 434.29
- AVTX N/A
- EPS
- PBYI 0.97
- AVTX N/A
- Revenue
- PBYI $238,062,000.00
- AVTX $441,000.00
- Revenue This Year
- PBYI N/A
- AVTX N/A
- Revenue Next Year
- PBYI N/A
- AVTX N/A
- P/E Ratio
- PBYI $4.75
- AVTX N/A
- Revenue Growth
- PBYI 8.63
- AVTX N/A
- 52 Week Low
- PBYI $2.25
- AVTX $3.39
- 52 Week High
- PBYI $6.07
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- PBYI 47.28
- AVTX 71.35
- Support Level
- PBYI $4.93
- AVTX $8.65
- Resistance Level
- PBYI $5.22
- AVTX $12.41
- Average True Range (ATR)
- PBYI 0.32
- AVTX 0.86
- MACD
- PBYI -0.10
- AVTX 0.10
- Stochastic Oscillator
- PBYI 7.37
- AVTX 75.00
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).